ALS News Today Home | ALS News Today
WEB6 days ago — ProJenX has teamed up with Unlearn, a company that specializes in artificial intelligence (AI), to create virtual twins of patients as a way of more quickly collecting data in a Phase 1 clinical trial of prosetin, its oral treatment candidate for amyotrophic lateral sclerosis (ALS). September 30, 2024 News by Steve Bryson, PhD.
Amyotrophic Lateral Sclerosis (ALS) Symptoms – ALS News Today
WEBFeb 6, 2023 — Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which worsening muscle weakness leads to movement problems and other symptoms such as trouble swallowing, speaking, and breathing. Patients also can experience digestive issues, mental health problems, and changes in behavior. Also known as …
Types of Amyotrophic Lateral Sclerosis (ALS) – ALS News Today
WEBMar 8, 2023 — Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that can be classified into different types based on factors like genetics, a patient’s family history, and the disorder’s early symptoms. Across all types, ALS is marked by the loss of motor neurons, the nerve cells that control voluntary muscle movements ...
Relyvrio for ALS – ALS News Today
WEBApr 11, 2024 — Relyvrio (sodium phenylbutyrate and taurursodiol) was an oral treatment approved in the U.S. and Canada to slow disease progression in adults with amyotrophic lateral sclerosis (ALS) that has now been discontinued. The therapy had shown in early clinical trials the ability to slow functional declines and to significantly extend patient survival ...
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
WEBAug 28, 2023 — Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic lateral sclerosis (ALS), in healthy people. The trial follows the clearance of Akava’s investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). It will be AKV9’s first-in-human study and is ...
News Archives - ALS News Today
WEBAmprion wins $100K to study causes of sporadic ALS. Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease. The project, led by Richard Smith, MD, state director of the Center for Neurologic Study ...
ALS support: Assistive equipment and adaptations | ALS ... - ALS …
WEBMay 26, 2023 — ALS is a progressive motor neuron disease that affects a person’s ability to control their muscle movements and leads to speaking, swallowing, mobility, and breathing issues. As muscles weaken, people living with ALS may need aids for eating and drinking, getting dressed, bathing, using the toilet, grooming, and for recreation and mobility.
ALS Facts and Statistics – ALS News Today
WEBThe disease is most common among people 60 years or older, but nearly 10 percent of ALS patients are 45 or younger. Although ALS is 20 percent more likely to develop in men than in women, with advancing age, the gender difference disappears. Moreover, Caucasians and non-Hispanics are more likely to develop ALS compared with other ethnic groups.
What is Amyotrophic Lateral Sclerosis (ALS)? | ALS News Today
WEBMar 20, 2023 — FAQs. Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder that damages nerve cells and causes disability. The condition also is known as Lou Gehrig’s disease, after the famed New York Yankees baseball player who was diagnosed with the disorder in the late 1930s. ALS specifically damages motor neurons, the nerve cells ...
ALS News Today Forums
WEBNavigating ALS Challenges. This is a space for discussing daily life and challenges related to ALS. Diagnosis Information and General Questions Mobility Aides, Assistive Technology and Medical Equipment ALS and Relationships. 14 hours ago.